A novel IDH1 inhibitor molecule, DS-1001b [134], demonstrated the property of inhibiting the growth of IDH1mut chondrosarcoma cells in vitro and in vivo and consequently also 2-HG overproduction due to the IDH1 mutation, similar to Ivosidenib, but with the additional effect of reducing the levels of H3K4me3 and H3K9me3, reversing the epigenetic process induced by 2-HG [135]. The gene discussed is IDH1; the disease is chondrosarcoma.